Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas McGranahan

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Nature|June 4, 2025
Y-chromosome loss in cancer and immune cells might worsen treatment outcomesNicholas McGranahan, Rahul Roychoudhuri
Cell|February 11, 2017
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureNicholas McGranahan, Charles Swanton
Trends in Cancer|January 27, 2021
Potential Use of Shared Frameshift Mutations in 'Off-the-Shelf' Neoantigen VaccinesKerstin Thol, Nicholas McGranahan
Science Translational Medicine|August 23, 2019
Neoantigen quality, not quantityNicholas McGranahan, Charles Swanton
Cell|August 26, 2017
Cancer Evolution Constrained by the Immune MicroenvironmentNicholas McGranahan, Charles Swanton
Cancer Cell|January 14, 2015
Biological and therapeutic impact of intratumor heterogeneity in cancer evolutionNicholas McGranahan, Charles Swanton
Cancer Cell|September 30, 2022
The importance of ancestry to understanding tumor mutation burden in cancerAlexandra Snyder, Nicholas McGranahan
Immunity|March 15, 2023
Persistence is key: Refining immunotherapy response predictionMichelle Leung, Nicholas McGranahan
Cancer Cell|April 3, 2026
Redefining cancer drivers with tissue-specific contextMaria Kalyva, Nicholas McGranahan
Cancer Cell|January 15, 2020
Cancer Genome Evolutionary Trajectories in MetastasisNicolai J Birkbak, Nicholas McGranahan
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Nature|June 4, 2025
Y-chromosome loss in cancer and immune cells might worsen treatment outcomesNicholas McGranahan, Rahul Roychoudhuri
Cell|February 11, 2017
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureNicholas McGranahan, Charles Swanton
Trends in Cancer|January 27, 2021
Potential Use of Shared Frameshift Mutations in 'Off-the-Shelf' Neoantigen VaccinesKerstin Thol, Nicholas McGranahan
Science Translational Medicine|August 23, 2019
Neoantigen quality, not quantityNicholas McGranahan, Charles Swanton
Cell|August 26, 2017
Cancer Evolution Constrained by the Immune MicroenvironmentNicholas McGranahan, Charles Swanton
Cancer Cell|January 14, 2015
Biological and therapeutic impact of intratumor heterogeneity in cancer evolutionNicholas McGranahan, Charles Swanton
Cancer Cell|September 30, 2022
The importance of ancestry to understanding tumor mutation burden in cancerAlexandra Snyder, Nicholas McGranahan
Immunity|March 15, 2023
Persistence is key: Refining immunotherapy response predictionMichelle Leung, Nicholas McGranahan
Cancer Cell|April 3, 2026
Redefining cancer drivers with tissue-specific contextMaria Kalyva, Nicholas McGranahan
Cancer Cell|January 15, 2020
Cancer Genome Evolutionary Trajectories in MetastasisNicolai J Birkbak, Nicholas McGranahan
Pageof 15